Treatment of Advanced Breast Cancer in Elderly Women: Medical Approach

• Parkin DM , BrayFI, DevesaSS: Cancer burden in the year 2000. The global picture.Eur. J. Cancer37, S4–S66 (2001).
   PubMed Web of Science ®Google Scholar
• Boyle P , FerlayJ: Cancer incidence and mortality in Europe 2004.Ann. Oncol.2, 68–75(2005).
   Google Scholar
• Kimmick GG , BalducciL: Breast cancer and aging. Clinical interactions.Hematol. Oncol. Clin. North Am.14(1), 213–34(2000)
   PubMed Web of Science ®Google Scholar
• Yancik R , WesleyMN, RiesLAet al.: Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA285(7), 885–892(2001).
   PubMed Web of Science ®Google Scholar
• Freyer G , BraudAC, ChaibiPet al.: Dealing with metastatic breast cancer in elderly women: results from a French study on a large cohort carried out by the ‘Observatory on Elderly Patients’ Ann. Oncol.17(2), 211–216(2006).
   PubMed Web of Science ®Google Scholar
• Holmes CA and Muss HB: Diagnosis and treatment of breast cancer in the elderly. Ca. Cancer J. Clin.53(4), 227–244(2003).
   PubMed Web of Science ®Google Scholar
• Saphner T , TormeyDC, GrayR: Annual hazard rates of recurrence for breast cancer after primary therapy.J. Clin. Oncol. (1996).
   PubMed Web of Science ®Google Scholar
• Diab SG , ElledgeRM, ClarckGM: Tumor characteristics and clinical outcome of elderly women with breast cancer.J. Natl Cancer Inst.92(7), 550–556(2000).
   PubMed Web of Science ®Google Scholar
• Basso U , BrunelloA, PoglianiC, MonfardiniS: Treatment options for early breast cancer in elderly women.Expert Rev. Anticancer Ther.4(2), 197–211(2004).
   PubMedGoogle Scholar
• Bonneterre J , BuzdarA, NabholtzJMet al.: Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer92, 2247–2258(2001).
   PubMed Web of Science ®Google Scholar
• Mouridsen H , GershanovichM, SunYet al.: Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J. Clin. Oncol.21, 2101–2109(2003).
   PubMed Web of Science ®Google Scholar
• Crivellari D , SunZ, CoatesASet al.: Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1–98 Trial. J. Clin. Oncol. (2008) (Epub ahead of print).
   PubMedGoogle Scholar
• Bonneterre J , ThurlimannB, Robertson JF et al.: Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J. Clin. Oncol.18(22), 3748–3757(2000).
   PubMed Web of Science ®Google Scholar
• Nabholtz JM , BuzdarA, PollakMet al.: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J. Clin. Oncol.18(22), 3758–3767(2000).
   PubMed Web of Science ®Google Scholar
• Mouridsen H , GershanovichM, SunYet al.: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a Phase III study of the International Letrozole Breast Cancer Group. J. Clin. Oncol.19(10), 2596–2606(2001).
   PubMed Web of Science ®Google Scholar
• Mauri D , PavlidisN, PlyzosNP, Ioannidis JP: Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J. Natl Cancer Inst.98(18), 1285–1291(2006).
   PubMedGoogle Scholar
• Monfardini S , BrunelloA, MolinoAet al.: Comorbidity and choice of adjuvant endocrine therapy in breast cancer patients (pts) older than 70 years. Proc. Am. Soc. Clin. Oncol.24, 8546 (2006).
   Google Scholar
• Chien AJ and Goss PE: Aromatase inhibitors and bone health in women with breast cancer. J. Clin. Oncol.20, 5305–5312, (2006).
   Google Scholar
• Donnellan PP , DouglasSL, CameronDA, LeonardRC: Aromatase inhibitors and arthralgia.J. Clin. Oncol.19(10), 2767 (2001).
   PubMed Web of Science ®Google Scholar
• Jonat W , HilpertF and Kaufmann M: Aromatase inhibitors: a safety comparison. Exp. Opin. Drug Saf.6, 165–174(2007).
   PubMed Web of Science ®Google Scholar
• Coleman RE , BoltenWW, LansdownMet al.: Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations. Cancer Treat. Rev. (2007) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Burstein HG . Aromatase inhibitor-associated arthralgia syndrome. Breast16(3), 223–234(2007).
   PubMed Web of Science ®Google Scholar
• Agrawal A , RobertsonJF, CheungKL: Resurrection of clinical efficacy after resistance to endocrine therapy in metastatic breast cancer.World J. Surg. Oncol.4, 40 (2006).
   PubMedGoogle Scholar
• Mouridsen H and Chaudri-Ross HA: Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer. Oncologist9, 497–506(2004).
   PubMed Web of Science ®Google Scholar
• Howell A , RobertsonJF, Quaresma Albano J et al.: Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J. Clin. Oncol.20(16), 3396–3403(2002).
   PubMed Web of Science ®Google Scholar
• Osborne CK , PippenJ, JonesSEet al.: Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial.J. Clin. Oncol.20, 3386–3395(2002).
   PubMed Web of Science ®Google Scholar
• Christman K , MussHB, CaseLD, Stanley V: Chemotherapy of metastatic breast cancer in the elderly – the Piedmont Oncology Association experience, JAMA268, 57–62(1992).
   PubMed Web of Science ®Google Scholar
• Miles D , von Minckwitz G, Seidman AD: Combination versus sequential single-agent therapy in metastatic breast cancer. Oncologist7(Suppl. 6), 13–19(2002).
   PubMed Web of Science ®Google Scholar
• Monfardini S , GridelliC, PasettoLMet al.: Vulnerable and frail elderly: an approach to the management of the main tumour types. Eur. J. Cancer (2008) (Epub ahead of print).
   Web of Science ®Google Scholar
• Prove A , BecquartD, DirixLet al.: Oral Idarubicin chemotherapy in elderly advanced breast cancer patients failing hormonal therapy: conclusive results. Proc. Am. Soc. Clin. Oncol.17, 167a (1998).
   Google Scholar
• Toffoli G , CrivellariD, LombardiDet al.: Innovative phase II study of chronic oral Idarubicin administration in elderly metastatic breast cancer with pharmacokinetic analyses. Proc. Am. Soc. Clin. Oncol.21(Abstract 1528) (2002) .
   Google Scholar
• Crivellari D , LombardiD, CoronaGet al.: Innovative schedule of oral idarubicin in elderly patients with metastatic breast cancer: comprehensive results of a Phase II multi-institutional study with pharmacokinetic drug monitoring. Ann. Oncol.17(5), 807–812(2006).
   PubMed Web of Science ®Google Scholar
• Repetto L , SimoniC, VenturinoAet al.: Mitoxantrone in elderly women with advanced breast cancer: a Phase II study. Anticancer Res.15(5B), 2297–2300(1995).
   PubMed Web of Science ®Google Scholar
• Sorio R , RobieuxI, GalligioniEet al.: Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. Eur. J. Cancer33(2), 301–303(1997).
   PubMed Web of Science ®Google Scholar
• Vogel C , O‘RourkeM, WinerEet al.: Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann. Oncol.10(4), 397–402(1999).
   PubMed Web of Science ®Google Scholar
• Wildiers H and Paridaens R: Taxanes in elderly breast cancer patients. Cancer Treat. Rev.30(4), 333–342(2004).
   PubMed Web of Science ®Google Scholar
• Breier S , LebedinskyC, AyiviriCet al.: Long-term weekly paclitaxel in metastatic breast cancer. A Phase II trial in pretreated patients. ASCO Annual Meeting Proceedings (Abstract 740) (1998).
   Google Scholar
• Smorenburg CH , ten Tije AJ, Verweij J et al.: Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer. Eur. J. Cancer39(2), 196–202(2003).
   PubMed Web of Science ®Google Scholar
• ten Tije AJ , SmorenburgCH, SeynaeveCet al.: Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre Phase II trial. Eur. J. Cancer40(3), 352–357(2004).
   PubMed Web of Science ®Google Scholar
• Del Mastro L , PerroneF, RepettoLet al.: Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a Phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer). Ann. Oncol.16(2), 253–258(2005).
   PubMed Web of Science ®Google Scholar
• Zanetta S , AlbrandG, BachelotTet al.: A Phase I trial of docetaxel every 21 days in elderly patients with metastatic breast cancer (MBC). Proc. 25th Congress of the European Society for Medical Oncology. Ann. Oncol.11(Suppl. 4), 73 (2000).
   Google Scholar
• Hainsworth JD , BurrisHA 3rd, Yardley DA et al.: Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network Phase II trial. J. Clin. Oncol.19(15), 3500–3505(2001).
   PubMed Web of Science ®Google Scholar
• Lorenzo I , ConstenlaM, PalaciosPet al.: Docetaxel as single-agent treatment in elderly patients with advanced breast cancer. Clin. Drug Investig.25(4), 249–256(2005).
   PubMed Web of Science ®Google Scholar
• Massacesi C , MarcucciF, BoccettiTet al.: Low dose-intensity docetaxel in the treatment of pre-treated elderly patients with metastatic breast cancer. Clin. Drug Investig.24(1), 43–48(2005).
   Google Scholar
• Bajetta E , ProcopioG, CelioLet al.: Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J. Clin. Oncol.23(10), 2155–2161(2005).
   PubMed Web of Science ®Google Scholar
• O‘Shaughnessy JA , BlumJ, MoiseyenkoVet al.: Randomized, open-label, Phase II trial of oral capecitabine (Xeloda®) vs a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann. Oncol.12(9), 1247–1254(2001).
   PubMed Web of Science ®Google Scholar
• Feher O , VodvarkaP, JassemJet al.: First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, Phase III study. Ann. Oncol.16(6), 899–908(2005).
   PubMed Web of Science ®Google Scholar
• Rha SY , MoonYH, JeungHCet al.: Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast Cancer Res. Treat.90(3), 215–221(2005).
   PubMed Web of Science ®Google Scholar
• O‘Brien ME , WiglerN, InbarMet al.: Reduced cardiotoxicity and comparable efficacy in a Phase III trial of pegylated liposomal doxorubicin HCl (Caelyx®/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol.15(3), 440–449(2004).
   PubMed Web of Science ®Google Scholar
• Coleman RE , BiganzoliL, CanneyPet al.: A randomised Phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). Eur. J. Cancer42(7), 882–887(2006).
   PubMed Web of Science ®Google Scholar
• Biganzoli L , ColemanR, MinisiniAet al.: A joined analysis of two European Organization for the Research and Treatment of Cancer (EORTC) studies to evaluate the role of pegylated liposomal doxorubicin (Caelyx®) in the treatment of elderly patients with metastatic breast cancer. Crit. Rev. Oncol. Hematol.61(1), 84–89(2007).
   PubMed Web of Science ®Google Scholar
• Hamberg P , VerweijJ and Seynaeve C: Cytotoxic therapy for the elderly with metastatic breast cancer: a review on safety, pharmacokinetics and efficacy, Eur. J. Cancer43, 1514–1528(2007).
   PubMed Web of Science ®Google Scholar
• Mammoliti S , MerliniL, CarotiC, GalloL: Phase II study of mitoxantrone, 5-fluorouracil, and levo-leucovorin (MLF) in elderly advanced breast cancer patients.Breast Cancer Res. Treat.37(1), 93–96(1996).
   PubMed Web of Science ®Google Scholar
• Pinotti G , ChiniC, ProserpioIet al.: Elderly metastatic breast cancer patients treated with mitoxantrone, levo-leucovorin and 5-fluorouracil (NFL), a Phase II multicentric study. Ann. Oncol.12(Suppl. 4), 24 (2001).
   Google Scholar
• Jagiello-Gruszfeld AI , PienkowskiT, GiermekJ: The combination of mitoxantrone and methotrexate in elderly patients with advanced breast cancer.Proc. Am. Soc. Clin. Oncol.21, 259b (2002).
   Google Scholar
• Rozzi A , PochiniM, ChiariotM, Lanzetta G. Epirubicin and infusional 5-fluorouracil for elderly patients with advanced breast cancer. Proceedings of the 8th International Conference on Geriatric Oncology (SIOG). Rome, Italy, November 21–22 (2003).
   Google Scholar
• Rozzi A , SalernoM, CiorraAAet al.: Vinorelbine and infusional 5-fluorouracil as first line chemotherapy in elderly patients with metastatic breast cancer: a Phase II study. Program and abstracts of the 25th San Antonio Breast Cancer Symposium; (Abstract 339). December 11–14, San Antonio, TX, USA (2002).
   Google Scholar
• Hess D , ThurlimannB, PaganiOet al.: Capecitabine and vinorelbine in elderly patients (≥65 years) with metastatic breast cancer: a Phase I trial (SAKK 25/99). Ann. Oncol.15(12), 1760–1765(2004).
   PubMed Web of Science ®Google Scholar
• Gennatas C , MichalakiV, MouratidouDet al.: Gemcitabine in combination with vinorelbine for heavily pretreated advanced breast cancer. Anticancer Res.26(1B), 549–552(2006).
   PubMed Web of Science ®Google Scholar
• Dinota A , BilanciaD, RomanoR, ManzioneL: Biweekly administration of gemcitabine and vinorelbine as first line therapy in elderly advanced breast cancer.Breast Cancer Res. Treat.89(1), 1–3(2005).
   PubMed Web of Science ®Google Scholar
• Basso U , FratinoL, BrunelloAet al.: Which benefit from adding gemcitabine to vinorelbine in elderly (≥70 years) women with metastatic breast cancer? Early interruption of a Phase II study. Ann. Oncol.18(1), 58–63(2007).
   PubMed Web of Science ®Google Scholar
• Addeo R , FaiolaV, GuarrasiRet al.: Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women ≥65 years of age. Cancer Chemother. Pharmacol.(2007) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Brunello A , BassoU, PoglianiCet al.: Which benefit from adding gemcitabine to vinorelbine in elderly (≥70 years) women with metastatic breast canver? Early interruption of a Phase II study. Ann. Oncol.18(1), 58–63(2007).
   PubMed Web of Science ®Google Scholar
• Cobleigh MA , VogelCL, TripathyDet al.: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol.17(9), 2639–2648(1999).
   PubMed Web of Science ®Google Scholar
• Slamon DJ , Leyland-JonesB, ShakSet al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med.344(11), 783–792(2001).
   PubMed Web of Science ®Google Scholar
• Burstein HJ , KuterI, CamposSMet al.: Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J. Clin. Oncol.19(10), 2722–2730(2001).
   PubMed Web of Science ®Google Scholar
• Paton VE , KleinP, LiebermanG: Trastuzumab (H) benefits both younger and older women with HER2 positive MBC.Proc. Am. Soc. Clin. Oncol.22, (Abstract 294) (2003).
   Google Scholar
• Giuliani R , MinisiniAM, PaesmanMet al.: Is age a risk factor of congestive heart failure (CHF) in patients receiving trastuzumab (T)? Results from two Belgian compassionate use programs in metastatic breast cancer patients. Proc. Am. Soc. Clin. Oncol.22, (Abstract 838) (2004).
   Web of Science ®Google Scholar
• Fyfe G , MassR, MurphyM, SlamonD: Older (age > 60) patients obtain survival benefit from herceptln plus chemotherapy.Eur. J. Cancer37(Suppl. 6), S189 (2001).
   PubMedGoogle Scholar
• Seidman A , HudisC, PierriMKet al.: Cardiac dysfunction in the trastuzumab clinical trials experience. J. Clin. Oncol.20(5), 1215–1221(2002).
   PubMed Web of Science ®Google Scholar
• Marcom PK , IsaacsC, HarrisLet al.: The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res. Treat.102(1), 43–49(2007).
   PubMed Web of Science ®Google Scholar
• Mackey JR , KaufmanB, ClemensMet al.: Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. Breast Cancer Res. Treat.100(Suppl. 1) (Abstract 3) (2006).
   Web of Science ®Google Scholar
• Miller K , WangM, GralowJet al.: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med.357(26), 2666–2676(2007).
   PubMed Web of Science ®Google Scholar
• Pasetto LM , FalciC, SinigagliaGet al.: How many colorectal cancer (CRC) Patients older than 70 years may be safely treated with bevacizumab? J. Clin. Oncol.Part I. 24, 18S (2006).
   Google Scholar
• Balducci L, Yates J: General guidelines for the management of older patients with cancer. Oncology (Huntingt.)14, 221–227(2000).
   PubMed Web of Science ®Google Scholar
• Extermann M , MeyerJ, McGinnisMet al.: A comprehensive geriatric intervention detects multiple problems in older breast cancer patients. Crit. Rev. Oncol. Hematol.49, 69–75(2004).
   PubMed Web of Science ®Google Scholar
• Extermann M , AaproM, BernabeiRet al.: Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit. Rev. Oncol. Hematol.55, 241–252(2005).
   PubMed Web of Science ®Google Scholar
• Katz S , FordAB, MoskowitzRWet al.: Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA.185, 914–919(1963).
   PubMed Web of Science ®Google Scholar
• Lawton MP , BrodyEM: Assessment of older people: self-maintaining and instrumental activities of daily living.Gerontologist3, 179–186(1969).
   Google Scholar
• Folstein MF , FolsteinSE, McMughPR: ‘Mini Mental State‘: a practical method for grading the cognitive state of patients for the clinician.J. Psychiatr. Res.12, 189–198(1975).
   PubMed Web of Science ®Google Scholar
• Hickie C and Snowdon J: Depression scales for the elderly: GDSClin. Gerontol.6, 51–53(1987).
   Google Scholar
• Charlson ME , PompeiP, AlesKet al.: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation.J. Chronic Dis.40, 373–383(1987).
   PubMedGoogle Scholar
• Miller MD , ParadisCF and Houck PR et al.: Rating chronic medical illness burden in gero-psychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res.41, 237–248(1992).
   PubMed Web of Science ®Google Scholar
• Kaufmann M , BajettaE, DirixLYet al.: Exemestane improves survival in metastatic breast cancer: results of a Phase III randomized study. Clin. Breast Cancer1(Suppl. 1), S15–S18 (2000).
   PubMedGoogle Scholar
• Howell A , RobertsonJF, AbramPet al.: Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J. Clin. Oncol.22(9), 1605–1613(2004).
   PubMed Web of Science ®Google Scholar
• Kurtz JE , DeplanqueG, BorelCet al.: Dose-finding study of oral idarubicin and cyclophosphamide in first-line treatment of elderly patients with metastatic breast cancer. Ann. Oncol.11(2), 229–30(2000).
   PubMed Web of Science ®Google Scholar

Websites

• Ries LAG, Harkins D, Krapcho M et al.: Cancer Statistics Review (1975) 2003. National Cancer Institute, MD, USA. http://seer.cancer.gov/csr/1975_2003/ (Accessed February2008).
   Google Scholar
• Surveillance, Epidemiology, and End Results (SEER) Program. Public use data (1973–1999). National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April (2002). www.seer.cancer.gov
   Google Scholar